Alterity Therapeutics (ASX:ATH) has announced the launch of a Phase 2 clinical trial of ATH434 in the U.S. for the treatment of Multiple System Atrophy (MSA), a rare rapidly progressive Parkinsonian disorder with no approved treatment.
The trial is a randomized, double-blind, placebo-controlled investigation of ATH434, which has been granted orphan designation by the U.S. FDA and the European Commission.
The study will evaluate the effect of ATH434 on neuroimaging and protein biomarkers, as well as safety and pharmacokinetics, and is expected to enroll 60 adults.
Wearable sensors will also be utilised to evaluate motor activities that are important to patients with MSA.
Following the announcement, shares of Alterity Therapeutics (ASX:ATH) were unchanged at $0.010.